Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 195-201

  Goldwasser, François ^a   Bozec, Laurence ^a   Zeghari Squalli, Nadia ^a   Misset, Jean Louis ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Chemotherapy; DACH platinum; DNA damage; DNA topoisomerase I; Synergism; Topotecan

Indexed keywords

CELL DNA; DNA TOPOISOMERASE; OXALIPLATIN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0032999031     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00008     Document Type: Article

References (36)

1. Ozols RF. Future directions in the chemotherapy of ovarian cancer. Semin Oncol 1997; 24: S15-86-90.
2. Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian cancer: current status and future directions. Semin Oncol 1997; 24: S2-1-9.
3. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments]. J Clin Oncol 1997; 15: 2183-93.
4. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kauf-mann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
5. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994; 54: 1431-9.
6. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995; 1262: 1-14.
7. Pommier Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol 1996; 23: 3-10.
8. Cheng M-F, Chaterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994; 6: 269-79.
9. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design [see comments]. J Natl Cancer Inst 1994; 86: 1517-24.
10. Kaufman SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734-41.
11. Ma J, Maliepaard M, Nooter K, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998; 41: 307-16.
12. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998; 41: 385-90.
13. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065-70.
14. Chaney SG. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). Int J Oncol 1995; 6: 1291-305.
15. Misset JL. Oxaliplatin in practice. Br J Cancer 1998; 77(Suppl 4): 4-7.
16. Raymond E, Faivre S, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12.
17. Page JD, Husain I, Sancar A, Chaney SG. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 1990; 29: 1016-24.
18. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv Exp Med Biol 1994; 370: 139-43.
19. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
20. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-5.
21. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65.
22. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757-66.
23. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg 1984; 22: 27-55.
24. Goldwasser F, Valenti M, Torres R, Pommier Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 1996; 2: 687-93.
25. Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 1994; 85: 966-71.
26. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995; 9: 1013-24.
27. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen. Cancer Res 1995; 55: 211'6-21.
28. 2-phase arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996; 56: 4430-7.
29. Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A, Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem 1997; 272: 26441-7.
30. Pourquier P, Ueng LM, Kohlhagen G, et al. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 1997; 272: 7792-6.
31. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266: 1954-6.
32. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992; 10: 1775-80.
33. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol 1994; 120: 2743-50.
34. Raymond E, Burris HA, Rowinsky EK, et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann Oncol 1997; 8: 1003-8.
35. Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan and cisplatin: phase I. pharmacologic, and in vitro studies to examine sequence dependence [see comments]. J Clin Oncol 1996; 14: 3074-84.
36. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995; 55: 2097-103.